🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: docetaxel + trastuzumab sc + pertuzumab

Found 17 matching trials

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

PHASE3

This is a Phase IIIb, multinational, multicenter, randomized, open-label st...

Status

Completed

Location

Centro de Investigaciones Médicas y Desarrollo LC S.R.L

Start Date

2022-07-05

Trial ID

NCT05415215

Treatments Being Tested

Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)Pertuzumab IV Trastuzumab IV Trastuzumab Emtansine Investigator's Choice of Chemotherapy Surgery Radiotherapy

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

PHASE2

The purpose of this trial is to evaluate efficacy and toxicity of either th...

Status

Active Not Recruiting

Location

Dept. of Oncology, Örebro University Hospital

Start Date

2014-11

Trial ID

NCT02568839

Treatments Being Tested

docetaxel + trastuzumab sc + pertuzumab trastuzumab emtansin

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

PHASE3

This randomized phase III trial studies docetaxel, carboplatin, trastuzumab...

Status

Completed

Location

Fairbanks Memorial Hospital

Start Date

2014-02-18

Trial ID

NCT02003209

Treatments Being Tested

Aromatase Inhibition Therapy Carboplatin Cytology Specimen Collection Procedure Docetaxel Goserelin Acetate Laboratory Biomarker Analysis Pertuzumab Quality-of-Life Assessment Therapeutic Conventional Surgery Trastuzumab Whole Breast Irradiation

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

PHASE3

This is an open-label, single-arm, multicenter, Phase IIIb study to evaluat...

Status

Completed

Location

AZ Sint Jan

Start Date

2015-05-06

Trial ID

NCT02402712

Treatments Being Tested

Docetaxel pertuzumab [Perjeta]trastuzumab [Herceptin]

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

PHASE2

This is a phase 2 study evaluating medical treatment before surgery in HER2...

Status

Terminated

Location

Sahlgrenska universitetssjukhuset

Start Date

2019-05-23

Trial ID

NCT03894007

Treatments Being Tested

Docetaxel Carboplatin Trastuzumab Pertuzumab Epirubicin Cyclophosphamide Atezolizumab Trastuzumab emtansine Paclitaxel

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

PHASE3

This study will evaluate the pharmacokinetics, efficacy, and safety of the ...

Status

Completed

Location

Peking University People's Hospital

Start Date

2020-02-05

Trial ID

NCT04024462

Treatments Being Tested

Pertuzumab IV Trastuzumab IV Pertuzumab and Trastuzumab FDC SC Doxorubicin Cyclophosphamide Docetaxel Surgery Post-Operative Radiotherapy Hormone Therapy

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

PHASE3

This Phase III, randomized, two-arm, open-label, multicenter study will eva...

Status

Active Not Recruiting

Location

Arizona Clinical Research Center, Inc

Start Date

2022-07-18

Trial ID

NCT05296798

Treatments Being Tested

Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocrine Therapy of Investigator's Choice

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

PHASE1

This phase Ib/II trial studies the side effects and best dose of ribociclib...

Status

Active Not Recruiting

Location

UCLA / Jonsson Comprehensive Cancer Center

Start Date

2022-04-07

Trial ID

NCT05319873

Treatments Being Tested

Carboplatin Docetaxel Fulvestrant Pertuzumab Quality-of-Life Assessment Ribociclib Trastuzumab Tucatinib

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

PHASE3

This is a global Phase III, two-arm, open-label, multicenter, randomized st...

Status

Completed

Location

Maryland Oncology Hematology

Start Date

2018-06-14

Trial ID

NCT03493854

Treatments Being Tested

Cyclophosphamide Doxorubicin Docetaxel Paclitaxel Pertuzumab IV FDC of Pertuzumab and Trastuzumab SC Trastuzumab IV Trastuzumab SC Surgery Post-operative Radiotherapy Hormone Therapy

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

PHASE2

The purpose of this study is to test the safety and effectiveness of a sequ...

Status

Recruiting

Location

Dana-Farber Cancer Institute

Start Date

2024-08-08

Trial ID

NCT06439693

Treatments Being Tested

Nab-Paclitaxel Paclitaxel Docetaxel Phesgo T-DM1 Pertuzumab Trastuzumab Deruxtecan Trastuzumab Subcutaneous Subcutaneous Tucatinib Trastuzumab

Previous Next